Angelie Noa, a nine-year-old Obu Munuvu, and her siblings would huddle in their bamboo hut every night to share the “spot ...

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show benefit in a second Phase III trial. The company is ...

Cassava Technologies has announced plans to build Africa’s first “AI Factory” — a high-performance, AI-enabled data center powered by NVIDIA’s advanced computing technology. At the ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies ...

Cassava Technologies, founded by Zimbabwean telecoms tycoon Strive Masiyiwa, has selected Nvidia to build Africa's first artificial intelligence factory The project will deploy Nvidia's advanced ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease Simufilam continued to ...

Global technology firm, Cassava Technologies, will partner American multinational corporation and technology company, Nvidia Corporation, to build Africa’s first artificial intelligence (AI ...

Cassava Technologies is building a new supercomputer in South Africa as part of what it claims is Africa’s “first AI factory.” It is the first stage of a plan to bring AI hardware to its data centers ...

Cassava Technologies partnered with Nvidia to build what the pair claimed would be Africa’s first AI factory, as part of a push around deploying the technology in the region. Cassava, founded by ...

Day after his house was attacked by Karni Sena, Samajwadi Party (SP) Rajya Sabha member Ramji Lal Suman on Thursday said he will not apologise, as he did not say anything wrong about Rana Sanga.

Cassava Sciences (SAVA) shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD. Topline data indicate that REFOCUS-ALZ did not meet each of the prespecified ...